| Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V ... Cancer Cell 36, 1–15, 2019 | 294* | 2019 |
| Translational control in the stress adaptive response of cancer cells: a novel role for the heat shock protein TRAP1 EF Matassa DS, Amoroso MR, Agliarulo I, Maddalena F, Sisinni L, Paladino S ... Cell Death & Disease 4, 2013 | 114 | 2013 |
| Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial BA Carneiro, B Konda, RB Costa, RLB Costa, V Sagar, DB Gursel, ... The Journal of Clinical Endocrinology & Metabolism 104 (12), 6193-6200, 2019 | 109 | 2019 |
| Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer R Vatapalli, V Sagar, Y Rodriguez, JC Zhao, K Unno, S Pamarthy, B Lysy, ... Nature communications 11 (1), 4153, 2020 | 77 | 2020 |
| Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both … BA Carneiro, KA Collier, RJ Nagy, S Pamarthy, V Sagar, S Fairclough, ... JCO precision oncology 2, 2018 | 62 | 2018 |
| Regulatory role of rpL3 in cell response to nucleolar stress induced by Act D in tumor cells lacking functional p53 A Russo, V Pagliara, F Albano, D Esposito, V Sagar, F Loreni, C Irace, ... Cell Cycle 15 (1), 41-51, 2016 | 56 | 2016 |
| Human rpL3 plays a crucial role in cell response to nucleolar stress induced by 5-FU and L-OHP D Esposito, E Crescenzi, V Sagar, F Loreni, A Russo, G Russo Oncotarget 5 (22), 11737, 2014 | 53 | 2014 |
| EphB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells Vinay Sagar, Rajita Vatapalli, Barbara Lysy, Sahithi Pamarthy, Jonathan F ... Cell Death & Disease 10 (11), 2019 | 44 | 2019 |
| Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib BA Carneiro, S Pamarthy, AN Shah, V Sagar, K Unno, HY Han, XJ Yang, ... Clinical Cancer Research 24 (12), 2732-2739, 2018 | 36 | 2018 |
| Overcoming immunosuppression in bone metastases ZZ Reinstein, S Pamarthy, V Sagar, R Costa, SA Abdulkadir, FJ Giles, ... Critical reviews in oncology/hematology 117, 114-127, 2017 | 36 | 2017 |
| TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: Relevance in human colorectal tumors DS Matassa, I Agliarulo, MR Amoroso, F Maddalena, L Sepe, MC Ferrari, ... Molecular oncology 8 (8), 1482-1494, 2014 | 33 | 2014 |
| Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A … A Arivazhagan, DM Kumar, V Sagar, IRP Patric, S Sridevi, B Thota, ... Journal of neuro-oncology 107, 289-297, 2012 | 31 | 2012 |
| A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression AG Holmes, JB Parker, V Sagar, MI Truica, PN Soni, H Han, GE Schiltz, ... Science Advances 8 (17), eabh3635, 2022 | 28 | 2022 |
| Activated ALK cooperates with N-Myc via Wnt/β-catenin signaling to induce neuroendocrine prostate cancer K Unno, ZR Chalmers, S Pamarthy, R Vatapalli, Y Rodriguez, B Lysy, ... Cancer research 81 (8), 2157-2170, 2021 | 28 | 2021 |
| PIM1 destabilization activates a p53-dependent response to ribosomal stress in cancer cells. V Sagar, S Caldarola, V Aria, V Monteleone, C Fuoco, C Gargioli, ... Oncotarget, 2016 | 24 | 2016 |
| A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer Y Rodríguez, K Unno, MI Truica, ZR Chalmers, YA Yoo, R Vatapalli, ... Cancer research 82 (11), 2110-2123, 2022 | 11 | 2022 |
| Inflammatory bowel disease induces inflammatory and pre-neoplastic changes in the prostate AS Desai, V Sagar, B Lysy, AB Weiner, OS Ko, C Driscoll, Y Rodriguez, ... Prostate cancer and prostatic diseases 25 (3), 463-471, 2022 | 8 | 2022 |
| A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer DJ VanderWeele, M Kocherginsky, S Munir, B Martone, V Sagar, ... Clinical Genitourinary Cancer 20 (6), 575-580, 2022 | 2 | 2022 |
| A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC). MC Burns, V Sagar, B Jovanovic, AK Morgans, DJ VanderWeele, ... Journal of Clinical Oncology 38 (6_suppl), TPS274-TPS274, 2020 | 2 | 2020 |
| combining anti-androgen therapy and PARP inhibition results in synergistic cytotoxicity of metastatic castration-resistant prostate cancer (mCRPC) cells S Pamarthy, V Sagar, RJ Vatapalli, Z Reinstein, MZ Ansari, BAC Filho, ... Cancer Research 77 (13_Supplement), 1114-1114, 2017 | 1 | 2017 |
